Gene Therapy: Years After Accelerated Approval, Will US FDA Still Be Asking ‘Does It Work?’

Retiring Office of Tissues and Advanced Therapies’ Director Wilson Bryan expects the expedited pathway will be used more frequently moving forward, but worries that ambiguous confirmatory trial results many years down the line will still leave efficacy questions unanswered.